📋About Recursion Pharmaceuticals
Updated September 16, 2026Recursion Pharmaceuticals (NASDAQ: RXRX) is an AI-driven drug discovery company using biology-scale datasets and machine learning to compress drug development from 12 years to 4-5. After merging with Exscientia in November 2024, Recursion offers end-to-end AI drug discovery from target identification through candidate optimization, with 5 clinical programs and partnerships with Sanofi, Roche, Bayer, and Merck.
🛠️Products & Tools (1)
Recursion PharmaceuticalsHealthcare AI
AI-driven drug discovery company using biology-scale datasets and machine learning to identify novel treatments, compressing the drug development timeline from 12 years to 4-5.
Keep track of the companies you’re watching
- Save the companies you want to follow
- Get ⚡ alerts when your saved companies change
- Every product they ship, cross-linked to 900+ AI tool profiles
- Today’s top AI Stories — the day’s most important AI news, free
Swipe for Recommended for you and My AI Tools
Your AI Hub — sample data. See desktop view example